Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
6
75%

Phase Distribution

2

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
6(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (25.0%)
Phase 26 (75.0%)

Trials by Status

terminated113%
completed788%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

NCT02715115
completedphase_2

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

NCT01366820
terminatedphase_2

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

NCT02100150
completedphase_2

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

NCT01894958
completedphase_2

Study of NNZ-2566 in Patients With Traumatic Brain Injury

NCT00805818
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02715115Phase 2

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Completed
NCT01366820Phase 2

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

Completed
NCT02100150Phase 2

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Terminated
NCT01894958Phase 2

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Completed
NCT00805818Phase 2

Study of NNZ-2566 in Patients With Traumatic Brain Injury

Completed
NCT01703533Phase 2

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Completed
NCT00961779Phase 1

Safety Study of NNZ-2566 in Healthy Female Subjects

Completed
NCT01420042Phase 1

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8